Orally bioavailable selective inhibitor of nuclear export (SINE; Exportin-1 or XPO1 inhibitor; IC50 values 2.1 nM, 41.8 nM, and 8.5 nM, for inhibition of the viability of OCI-Ly3, OCI-Ly10, and CLBL1, respectively). Verdinexor (KPT 335) potently and selectively inhibits vRNP export and effectively inhibits the replication of various influenza virus A and B strains in vitro and in vivo. KPT 335 induced apoptosis in CLBL1 cells and primary canine DLBCL cells indicating good in vitro single agent activity against canine malignant melanoma.

KEYWORDS: KPT 335 | supplier | XPO1/CRM1 inhibitor | Verdinexor | KPT335 | CAS [1392136-43-4] | [1421923-73-0] | DNA-RNA | Exportin-1 | CRM1 | canine | melanoma | influenza | nuclear export | transporter | chaperone